Haolin Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Haolin Cai has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Fei Hou
Department of Nuclear Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China
36 shared publications - Hongbo Zhao
Department of Laboratory Animal Science, Kunming Medical University, Kunming, China
36 shared publications - Lin Lu
Institute of Biomedical Engineering Kunming Medical University Kunming Yunnan China
36 shared publications - Ting Chen
Department of Nuclear Medicine, Fuwai Yunnan Cardiovascular Hospital, Chinese Academy of Medical Sciences (Affiliated Cardiovascular Hospital of Kunming Medical University), Kunming, 528 Shahe North Road, Wuhua District, China.
36 shared publications - Xiaoqi Peng
Department of Nuclear Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China
36 shared publications - Yinghui Wang
Department of Nuclear Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China
36 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 31 October 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 77, 102913
Development and validation of an interpretable machine learning model for predicting the risk of distant metastasis in papillary thyroid cancer: a multicenter study
- 31 October 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 77, 102913
Top Cited PapersOpen AccessDevelopment and validation of an interpretable machine learning model for predicting the risk of distant metastasis in papillary thyroid cancer: a multicenter study
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S5. Protein expression categorized into 4 levels.
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S5. Protein expression categorized into 4 levels.
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Table S2. Relevant clinical information of 44 LMDTC and 25 NMDTC patients used for 4D Label-free proteomic analysis, PRM, and IHC dual validation
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Table S2. Relevant clinical information of 44 LMDTC and 25 NMDTC patients used for 4D Label-free proteomic analysis, PRM, and IHC dual validation
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Table S6. Proteins with degree>40 in the PPI network
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Table S6. Proteins with degree>40 in the PPI network
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S4. WGCNA analysis of the proteomics data.
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S4. WGCNA analysis of the proteomics data.
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Material S1 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
KEGG Analysis Table of Differential Proteins
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Material S1 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
KEGG Analysis Table of Differential Proteins
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Table S3. Conditions for setting up PRM quantitative peptide segments
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Table S3. Conditions for setting up PRM quantitative peptide segments
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S2. Principal component analysis of patients in LMDTC (M) group and NMDTC (NM) group.
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S2. Principal component analysis of patients in LMDTC (M) group and NMDTC (NM) group.
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S1. Statistical chart of protein identification results.
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S1. Statistical chart of protein identification results.
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Table S5. Enrichment analysis of 418 DEPs in KEGG pathways. The top 20 enriched pathways were selected to construct pathway-gene networks and sorted based on degree values, resulting in 25 DEPs
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Table S5. Enrichment analysis of 418 DEPs in KEGG pathways. The top 20 enriched pathways were selected to construct pathway-gene networks and sorted based on degree values, resulting in 25 DEPs